In re: Application of Ekwuribe et al.

Serial No.: 09/429,798 Filed: 29 October 1999

Page 18

In the Claims:

Please replace the following amended claims with the clean versions that follow hereinbelow:

7. (Amended) The amphiphilic drug-oligomer conjugate of claim 1 wherein the therapeutic compound is [met⁵]enkephalin (SEQ ID NO:48).

20. (Amended) An amphiphilic oligomer-enkephalin conjugate selected from the group consisting of:

$$HN - C(O) - OC_2H_4 - OC_2H_4 - N - C(O)CH_2CH_2 - (CH = CH - CH_2)_6CH_3$$
 (SEQ ID NO:1);

H₂N-Tyr-Gly-Gly-Phe-Met-Lys-COOH

$$HN - C(O) - OC_2H_4 - OC_2H_4 - N - C(O)(CH_2)_7 - CH = CH - CH_2 - CH = CH - (CH_2)_4 - CH_3$$
 (SEQ ID NO:1);

/ H₂N-Tyr-Gly-Gly-Phe-Met-Lys-COOH

$$HN - C(O) - OC_2H_4 - OC_2H_4 - O-(CH_2)_{15} - CH_3$$
 (SEQ ID NO:1);

H₂N-Tyr-Gly-Gly-Phe-Met-Lys-COOH

$$HN - C(O) - O - (C_2H_4O)_3 - C(O) - (CH_2)_{14} - CH_3$$
 (SEQ ID NO:1); and

 $C(O)-O-(C_2H_4O)_3-C(O)-(CH_2)_{14}-CH_3$

$$HN - C(O) - O - (C_2H_4O)_3 - C(O) - (CH_2)_{14} - CH_3$$
 (SEQ ID NO:2).

In re: Application of Ekwuribe et al.

Serial No.: 09/429,798 Filed: 29 October 1999

Page 19

21. (Amended) An amphiphilic oligomer-enkephalin conjugate wherein the oligomer is comprised of a lipophile and a hydrophile and the lipophile is coupled to the hydrophile by a hydrolyzable bond, said conjugate being selected from the group consisting of:

$$\begin{array}{c} O \\ | I \\ H_2N\text{-Tyr-Gly-Gly-Phe-Met-Lys-C-OH} \\ HN & --- C(O)\text{-OC}_2H_4\text{-OC}_2H_4\text{-N-C(O)CH}_2\text{-CH}_2\text{-(CH=CH-CH}_2)}_6\text{CH}_3 & \textbf{(SEQ ID NO:1)}; \end{array}$$

H₂N-Tyr-Gly-Gly-Phe-Met-Lys-COOH

$$HN - C(O) - OC_2H_4 - OC_2H_4 - N - C(O)(CH_2)_7 - CH = CH - CH_2 - CH = CH - (CH_2)_4 - CH_3$$
 (SEQ ID NO:1); and

Tyr-Gly-Gly-Phe-Met-Lys-COOH

$$HN - C(O) - OC_2H_4 - OC_2H_4 - O-(CH_2)_{15} - CH_3$$
 (SEQ ID NO:1).

22. (Amended) An amphiphilic oligomer-enkephalin conjugate wherein the oligomer is comprised of a lipophile and a hydrophile and the lipophile is coupled to the hydrophile by a non-hydrolyzable bond, said conjugate being selected from the group consisting of:

$$\begin{array}{c} \text{H}_2\text{N-Tyr-Gly-Gly-Phe-Met-Lys-COOH} \\ \text{HN----} C(\text{O})\text{-O-CH}_2\text{-}(\text{C}_2\text{H}_4\text{O})_2\text{-CH}_2\text{-C(O)-O} \end{array} \tag{SEQ ID NO:1)};$$

H₂N-Tyr-Gly-Gly-Phe-Met-Lys-COOH
HN——
$$C(O)$$
-O- $(C_2H_4O)_3$ - $C(O)$ - $(CH_2)_{14}$ - CH_3 (SEQ ID NO:1); and

$$C(O)$$
-O- $(C_2H_4O)_3$ -C (O) - $(CH_2)_{14}$ - CH_3
HN-Tyr-Gly-Gly-Phe-Met-Lys-COOH
HN-C (O) -O- $(C_2H_4O)_3$ -C (O) - $(CH_2)_{14}$ - CH_3 (SEQ ID NO:2).